65276-90-6

Upstream product

• 55715-03-2 4-bromomethyl-3-nitrobenzoic acid 
• 115-11-7 isobutene 
• 6232-88-8 4-bromomethylbenzoic Acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 64-04-0 phenethylamine 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 147290-84-4 t-butyl 3-amino-4-[N-(t-butoxycarbonyl)-N-(2-phenylethyl)aminomethyl]benzoate 
• 147290-87-7 methyl (R,S)-8-carboxy-2,3,4,5-tetrahydro-3-oxo-4-(2-phenylethyl)-1H-1,4-benzodiazepine-2-acetate 
• 161014-59-1 methyl (R,S)-8-chlorocarbonyl-1,2,4,5-tetrahydro-3-oxo-4-(2-phenylethyl)-3H-1,4-benzodiazepine-2-acetate 
• 147291-71-2 2-[5-Carboxy-2-(phenethylamino-methyl)-phenylamino]-succinic acid dimethyl ester 
• 147290-83-3 4-[(tert-Butoxycarbonyl-phenethyl-amino)-methyl]-3-nitro-benzoic acid tert-butyl ester 
• 147290-89-9 methyl (R,S)-8-[[[4-(aminoiminomethyl)phenyl]amino]-carbonyl]-1,2,4,5-tetrahydro-3-oxo-4-(2-phenylethyl)-3H-1,4-benzodiazepine-2-acetate 
• 161014-58-0 (Z)-2-{5-tert-Butoxycarbonyl-2-[(tert-butoxycarbonyl-phenethyl-amino)-methyl]-phenylamino}-but-2-enedioic acid dimethyl ester 
• 147290-86-6 2-{5-tert-Butoxycarbonyl-2-[(tert-butoxycarbonyl-phenethyl-amino)-methyl]-phenylamino}-succinic acid dimethyl ester 
• 147290-88-8 [8-(4-{Amino-[(Z)-benzyloxycarbonylimino]-methyl}-phenylcarbamoyl)-3-oxo-4-phenethyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl]-acetic acid methyl ester 
• 1057650-72-2 C₂₃H₂₃ClN₄O₄S₂ 
• 130029-59-3 C₁₂H₁₆N₂O₄ 
• 1057652-41-1 C₁₇H₁₇ClN₂O₅S 
• 1057652-42-2 C₁₇H₁₉ClN₂O₃S 
• 1057649-44-1 C₂₇H₃₁ClN₄O₄S₂ 

Relevant academic research and scientific papers

Orally active zwitterionic factor Xa inhibitors with long duration of action

We have optimized 2-aminomethylphenylamine derivative as a factor Xa inhibitor. Several polar functional groups were introduced in the central phenyl ring, and we focused on zwitter ionic compound showing continuous inhibitory activity in oral administrat

Bicyclic fibrinogen antagonists

This invention relates to compounds of the formula: STR1 wherein A1 to A5 form an accessible substituted seven-membered ring, which may be saturated or unsaturated, optionally containing up to two heteroatoms chosen from the group of O, S and N wherein S and N may be optionally oxidized; D1 to D4 form an accessible substituted six membered ring, optionally containing up to two nitrogen atoms; R is at least one substituent chosen from the group of R7, or Q--C1-4 alkyl, Q--C2-4 alkenyl, Q--C2-4 alkynyl, preferably substituted by an acidic function; R* is H, Q--C1-6 alkyl, Q--C1-6 oxoalkyl, Q--C2-6 alkenyl or Q--C2-4 alkynyl, C3-6 cycloalkyl, Ar or Het, optionally substituted by one or more substitutents; and R6 is preferably a substituent containing a basic nitrogen moiety; or a pharmaceutically acceptable salt thereof, which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.